Chiara F. Sugrue, MBA, MS, SCT(ASCP)

More documents

Recommendations

Info

FNA Rapid On‐Site Assessment of Adequacy (FNA ROSA) performed by Cytotechnologists STAKEHOLDERS • Patients • Laboratory Professionals • Laboratory Administrators • Medical Specialists (Radiology , ENT, Oncology, etc) • Payers 4
FNA Rapid On‐Site Assessment of Adequacy (FNA ROSA) performed by Cytotechnologists ADVANTAGES • Allows appropriate specimen triage • IHC, Flow cytometry, Microbiology, Tissue bank for microRNA, • Reduces cost of patient care • Decreases number of unsatisfactory specimens • Decreases number of unnecessary surgery • Improves communication with clinicians • Allows better collection of clinical history • Brings the lab to the patient • “It is the right thing to do for the patient” 5
Page 1 and 2: CHIARA SUGRUE, MBA, MS, SCT(ASCP)CM
Page 3: EXTENDED ROLE OF CYTOTECHNOLOGISTS
Page 7 and 8: FNA Rapid Onsite Assessment of Adeq
Page 9 and 10: FNA TEAM @ NSLIJHS Laboratories Fro
Page 11 and 12: FNA Rapid On‐Site Assessment of A
Page 13 and 14: Lab productivity loss: example Spec
Page 15 and 16: DISADVANTAGE: Inadequate service co
Page 17 and 18: • New ways to apply technology
Page 19 and 20: Telepathology validation at NSLIJHS
Page 21 and 22: Option 3: Propose a new CPT code fo
Page 23 and 24: New model for FNA rapid on‐site A

Chiara F. Sugrue, MBA, MS, SCT(ASCP)

Create successful ePaper yourself

Delete template?

Save as template?